Kowa Company Limited

Yukiyoshi Yamazaki

Masahiro Nishikawa

Yoshinori Kyotani

Masahiro Tamura

Toshiaki Oda

Takeshi Doi

Tatsuhiko Kodama

Takaaki Araki

Kimiyuki Shibuya

Masao Ohkuchi

Ayumu Okuda

Shunji Takemura

Tsutomu Toma

Minoru Koura

Kazutoyo Abe

Hidefumi Ozawa

Soichi Oda

Takahiro Kitamura

Tetsuya Ishikawa

Keisuke Inoue

Tadaaki Ohgiya

Hajime Yamada

Hiroyuki Ishiwata

Takayuki Matsuda

Hiromichi Shigyo

Hideo Yoshizaki

Tomoyuki Koshi

Shinsuke Itoh

Takahisa Ogamino

Yoshiharu Miyake

Natsuyo Kumai

Kyoko Kotaki

Shin Tanikawa

Yuriko Habata

Okihisa Tokuda

Tomoaki Fukuda

Tatsuhiko Kodoma

To provide a method for improving optical purity of an optically active 2-hydroxycarboxylic acid or a derivative thereof, which is useful as a raw material in the manufacture of medicines, agrochemicais, and industrial products. The method of the invention for improving purity of a hydroxycarboxylic acid of the following formula (1a) or (1b) or a derivative thereof includes the steps of reacting the hydroxycarboxylic acid of the following formula (1a) or (1b) with at least one optically inactive base selected from the group consisting of an alkali metal, alkoxide and a secondary amine in the presence of a solvent and, subsequently, performing recrystallization, to thereby form a hydroxycarboxylic acid salt of the following formula (IIIa) or (IIIb): wherein Rrepresents a Calkyl group, and Rrepresents an alkali metal or a secondary amine.

Method for improving optical purity of 2-hydroxycarboxylic acid or derivative thereof

The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic &#x3b2;-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group;Rand R, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo Calkyl group, a Caryl group, a cyano group, a Calkyl group optionally having a substituent, a Calkenyl group optionally having a substituent, etc.; Rrepresents a hydrogen atom, a Calkyl group optionally having a substituent, etc.; and Rrepresents a hydrogen atom, a halogen atom, a Calkyl group optionally having a substituent, etc.]

Spiroindoline compound, and medicinal agent comprising same

A process for obtaining a compound (1) and an intermediate thereof in high yield and high optical yield is provided. A process for producing a compound (4), the process including reacting a compound (2) with a compound (3) in the presence of a base; and a process for producing a compound (1), the process including reacting a compound (2) with a compound (3) in the presence of a base to yield a compound (4) and then deesterifying the compound (4). wherein R represents an alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 8 carbon atoms.

Process for production of optically active PPAR-activating compound and intermediate of the same

A process for producing an optically active 2-hydroxybutyric ester represented by formula (1): by reacting an optically active 2,3-epoxypropionic ester represented by formula (2): with a methyl Grignard reagent CHMgX in the presence of a copper catalyst in an amount of 0.05 to 0.5 mol with respect to 1 mol of the 2,3-epoxypropionic ester.

Process for producing optically active 2-hydroxybutyric ester

The invention provides a process for producing an optically active butyric acid compound and a production intermediate therefore at high yield and high purity. The present invention provides a process for producing Compound (6), including reacting Compound (1) with optically active 2-trifluoromethanesulfonyloxybutyrolactone (2) in the presence of a base or reacting optically active 2-hydroxybutyrolactone (2) under Mitsunobu reaction conditions, to thereby form Compound (3); reacting Compound (3) with an alcohol and a halogenating agent, to thereby form Compound (4); dehalogenating Compound (4), to thereby form Compound (5); and de-esterifying Compound (5). 

Processes for production of optically active PPAR-activating compounds and intermediates for production thereof

A process for producing an optically active 2-hydroxybutyric ester (1), characterized by including reacting an optically active 2,3-epoxybutyric ester (2) with a thiol in the presence of scandium trifluoromethanesulfonate or ytterbium trifluoromethanesulfonate, to thereby produce Compound (3), and subjecting Compound (3) to desulfurization reaction: (wherein R represents a C1 to C6 alkyl group or a C7 or C8 aralkyl group; Rrepresents a C1 to C12 alkyl group or a phenyl group; and * represents S- or R-absolute configuration). The present invention provides a process for producing an optically active 2-hydroxybutyric ester at high yield and high optical purity.

Process for producing optically active ester

The present invention provides a production intermediate for compound (A-1) and a method for producing the intermediate at high yield and high optical yield.

Optically active PPAR-activating compound intermediate and method for producing same

The present invention provides a compound selectively activating PPAR&#x3b1;, which is useful as a medicament. The present invention is specifically directed to a benzoic acid derivative represented by the following general formula (1): wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a carboxy-alkyl group; X represents an oxygen atom, an NH group, or an S(O)group (wherein n represents an integer of 0, 1, or 2); and m represents an integer from 2 to 8; or a salt thereof. The present invention also provides a medicament comprising the benzoic acid derivative or the salt thereof as an active ingredient.

PPAR-activating compound

A compound represented by the following formula (1): (wherein each of Rand R, which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R, R, R, and R, which may be identical to or different from each other, represents a hydrogen atom, a halogen atom, a nitro group, a hydroxyl group, a Calkyl group, a trifluoromethyl group, a Calkoxy group, a Calkylcarbonyloxy group, a di-Calkylamino group, a Calkylsulfonyloxy group, a Calkylsulfonyl group, a Calkylsulfinyl group, or a Calkylthio group, or Rand R, or Rand Rmay be linked together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N&#x2014;R(Rrepresents a hydrogen atom, a Calkyl group, a Calkylsulfonyl group, or a Calkyloxycarbonyl group); Y represents an oxygen atom, S(O)(l is a number of 0 to 2), a carbonyl group, a carbonylamino group, an aminocarbonyl group, a sulfonylamino group, or an aminosulfonyl group; Z represents CH or N; n is a number of 1 to 6; and m is a number of 2 to 6) or a salt thereof; and therapeutic drugs containing any of such a compound or salt.

PPAR-activating compound and pharmaceutical composition comprising the compound

A cyclic diamine compound of formula (1): wherein Rand Rare individually a hydrogen atom or a methoxy group, provided Ris a methoxy group when Ris a hydrogen atom, or a hydrogen atom when Ris a methoxy group; A is an oxygen atom, a sulfur atom, CH&#x2550;CH, CH&#x2550;N or NR, in which Ris a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; B is a nitrogen atom, CH or CR, in which Ris a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; m is 1 or 2; and n is a number of 1 to 5,an acid-addition salt thereof, or a hydrate thereof. The compound has inhibitory effects on cell adhesion and is useful for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation.

Cyclic diamine compound with condensed-ring groups

A compound represented by the following general formula (1), a salt thereof, or an ester thereof: wherein m represents an integer of 0 to 4, n represents an integer of 5 to 9, and R represents hydrogen atom or a protective group of hydroxyl group, which has reducing actions of blood glucose, plasma insulin, and triglyceride, and is useful for preventive and/or therapeutic treatment of diabetes, complications of diabetes, hyperlipemia and others.

Carboxylic compound and medicine comprising the same

A compound represented by the following formula (1): Or a salt thereof; and therapeutic durgs containing the compound. The compound selectively activates PPAR&#x3b1;.

A cyclic amine compound represented by the following general formula (1):wherein, These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Growing community of inventors

Higashimurayama, Japan

Yukiyoshi Yamazaki